Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132527 | 1.00 | HSD17B3 (0.67) | HSD17B3PKMSLC6A19BACE1TTR | |
| SCHEMBL8315251 | 0.93 | HSD17B3 (0.58) | HSD17B3PKMSLC6A19BACE1TTR | |
| SCHEMBL8315248 | 0.93 | HSD17B3 (0.58) | HSD17B3PKMSLC6A19BACE1TTR | |
| SCHEMBL69618 | 0.88 | TTR (0.66) | TTRAPPMEN1KMT2AHTT | |
| SCHEMBL17157974 | 0.84 | HSD17B3 (0.63) | HSD17B3PKMSLC6A19BACE1POLB | |
| SCHEMBL17157975 | 0.84 | HSD17B3 (0.63) | HSD17B3PKMSLC6A19BACE1POLB | |
| SCHEMBL3065424 | 0.83 | CA12 (0.66) | TTRAPPMEN1KMT2APTPN1 | |
| SCHEMBL2631340 | 0.83 | CA12 (0.66) | TTRAPPMEN1KMT2APTPN1 | |
| SCHEMBL30676338 | 0.83 | CA12 (0.66) | TTRAPPMEN1KMT2APTPN1 | |
| SCHEMBL4081652 | 0.83 | PKM (0.70) | HSD17B3PKMSLC6A19BACE1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4509500-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6063789-A | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| US-5807866-A | Process for preparing N-benzyl indoles | THE UNIVERSITY OF EAST ANGLIA (GB) | 1998-09-15 | — | — | US | disclosed |
| EP-0775694-A2 | Process for preparing N-benzyl indoles | University of East Anglia (GB) | 1997-05-28 | — | — | EP | disclosed |
| US-4713486-A | ANTIALLERGENS | BEECHAM GROUP P.L.C. (GB) | 1987-12-15 | — | — | US | disclosed |
| EP-0109225-B1 | ARACHIDONIC ACID ANALOGUES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN MEDICINE | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0109225-A1 | Arachidonic acid analogues, processes for their preparation and their use in medicine | BEECHAM GROUP PLC (GB) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | HSD17B3 286/4885PKM 1452/4885SLC6A19 4236/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | HSD17B3 319/4885PKM 1609/4885SLC6A19 4233/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | HSD17B3 105/4885PKM 533/4885SLC6A19 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.